Macrophages loaded CpG and GNR-PEI for combination of tumor photothermal therapy and immunotherapy

Chen, Jie; Lin, Lin; Yan, Nan; Hu, Yingying; Fang, Huapan; Guo, Zhaopei; Sun, Pingjie; Tian, Huayu; Chen, Xuesi

doi:10.1007/s40843-018-9238-6

Cited by 31 publications

(16 citation statements)

References 36 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to biomechanical factors, biochemical factors and nonmalignant cells, such as CAFs, immune cells, and endothelial cells in tumor microenvironment, can all affect therapeutic responses [16][17][18]. CAFs constitute a majority of the structural scaffold of solid tumors and play a critical role in tumor survival and progression via secretion of various growth factors, cytokines, and chemokines and degradation of extracellular matrix proteins [19].…”

Section: Introductionmentioning

confidence: 99%

Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy

et al. 2019

View full text Add to dashboard Cite

Carcinoma-associated fibroblasts (CAFs) function as a double-edged sword in tumor progression. However, factors affecting the transition between tumor promotion and inhibition remain to be investigated. Here, we found that the transition was determined by stiffness heterogeneity of the tumor stroma in which tumor cells and CAFs were grown. When tumor cells were grown on a rigid plastic substrate, supernatants from CAFs inhibited the cytotoxic effects of 5fluorouracil. In contrast, when tumor cells were grown on a soft substrate (5.3 kPa), supernatants from CAFs grown on a soft substrate increased the cytotoxicity of 5-fluorouracil. The diverse effects of CAFs were mediated by mechanotransduction factors, including stroma stiffness-induced cytokine expression in CAFs and signal transduction associated with stress fiber formation of CAFs. Moreover, we found that the cytokine expression in CAFs was regulated by nuclear Yesassociated protein, which changed according to cell stiffness, as characterized by atomic force microscopy. Overall, these findings suggested that modulating the mechanotransduction of the stroma together with CAFs might be important for increasing the efficacy of chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The combination therapy in cancer treatment achieved rapid development in both research and clinical practice [1,2]. As we all know, due to the poor permeability of cytotoxic drugs in solid tumors, more and more attention has been paid to the combination therapy consisting of vascular disrupting agents (VDAs) [3,4], which can block the nutrients and oxygen supply by destroying the tumor vessels.…”

Section: Introductionmentioning

confidence: 99%

A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors. For this purpose, tumor-microenvironment stimuliresponsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol (HNK) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to a glutathione (GSH)-responsive nanocarrier, poly(α-lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites, achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy.

show abstract

“…In addition, the antigens released by dead tumor cells and the CpG adjuvant activated the body's antitumor immune response and ultimately effectively inhibited the growth of the tumor. [120] In another study, it was found that macrophages significantly improved the tumor-targeted delivery of NPs. The system ((WO+ICG)@ PLGA NP-loaded macrophages) significantly suppressed the tumor through immunotherapy and PTT in the B16 subcutaneous tumor model.…”

Section: Innate Immune-cell-based Antitumor Immunotherapeuticsmentioning

confidence: 98%

“…Macrophages are living cell carriers that use endocytosis to engulf anticancer drugs and deliver them and have strong drug tolerance and innate phagocytotic capabilities. [120] Chen and coworkers prepared macrophages loaded with the immune adjuvant CpG and gold nanorod (GNR)-polyethylenimine (PEI). Macrophages loaded with GNR-PEI/CpG obviously promoted drug accumulation in the tumor and significantly enhanced the effect of photothermal tumor therapy.…”

Section: Innate Immune-cell-based Antitumor Immunotherapeuticsmentioning

confidence: 99%

Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy

Pan

Zheng

et al. 2021

Advanced Materials

View full text Add to dashboard Cite

limitations, such as serious side effects, and are ineffective against subclinical metastasis and recurrence. [1] Recently, precision medicine approaches, such as novel targeting therapy, genomic and proteomic analysis, have become the mainstream in cancer clinical trials, but only 11-23% of the patients had an objective responses. [2,3] Current treatment strategies have generated good therapeutic effects and conquered some unwanted adverse impacts via improved biodistribution and accumulation of antitumor drugs to some degree, but these systems are still limited by their unsatisfactory target delivery efficacy. [4] Moreover, the treatment effect and patient objective response to monotherapy are also seriously limited by complex biological barriers and immunosuppression. [5] Encouragingly, these current challenges in cancer care, such as serious adverse events, poor tumor penetration, and intense drug resistance, have strongly prompted the continuous development of novel alternative approaches.Nanomedicine is an important application of synthetic material engineering in the medical field to improve tumor diagnostic imaging, facilitate targeted drug delivery, and enhance antitumor capabilities. Conventional synthetic nanotherapeutics, including protein/polymer-drug conjugates, liposomal preparations, dendrimers, and inorganic nanoparticles (NPs), have been investigated in lab or clinical research. [6] Synthetic materials constructed by lipid bilayers with active targeting peptide or cell-targeting antibodies have been proved to exhibit efficient delivery and cytotoxicity for tumor cell. [7,8] The advantages of synthetic materials, such as suitable size, targeting delivery, and appropriate surface chemistry, have the potential to enable therapeutic agents to better reach tumor site via tumor active targeting or enhanced permeability and retention (EPR) effect. However, only a few of the proposed engineered materials are currently in clinical use for patients or in preclinical trials, and most material agents are still subjected to unsatisfied targeting delivery and complex tumor microenvironment barriers. [9] The efficiency and accuracy of targeted delivery of synthetic materials are still not satisfactory because they depend on only the active or passive targeting of nanomedicine. Particularly, the majority of NPs circulating in the blood are typically removed by the in vivo mononuclear phagocyte system, which forms a rigorous biological barrier for nanomedicine transport. [10] In addition, tumor microenvironment (TME) Numerous clinical trials for cancer precision medicine research are limited due to the drug resistance, side effects, and low efficacy. Unsatisfactory outcomes are often caused by complex physiologic barriers and abnormal immune events in tumors, such as tumor target alterations and immunosuppression. Cell/bacteria-derived materials with unique bioactive properties have emerged as attractive tools for personalized therapy in cancer. Naturally derived bioactive materials, such as cell and bacterial t...

show abstract

Macrophages loaded CpG and GNR-PEI for combination of tumor photothermal therapy and immunotherapy

Cited by 31 publications

References 36 publications

Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy

Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy

A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy

Contact Info

Product

Resources

About